Financial Review: Atara Biotherapeutics (NASDAQ:ATRA) and INmune Bio (NASDAQ:INMB)

Atara Biotherapeutics (NASDAQ:ATRA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Institutional & Insider Ownership

91.8% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 0.4% of INmune Bio shares are held by institutional investors. 7.0% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 67.7% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Atara Biotherapeutics and INmune Bio, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics 1 2 7 0 2.60
INmune Bio 0 0 2 0 3.00

Atara Biotherapeutics presently has a consensus price target of $31.00, suggesting a potential upside of 120.17%. INmune Bio has a consensus price target of $12.25, suggesting a potential upside of 139.26%. Given INmune Bio’s stronger consensus rating and higher possible upside, analysts plainly believe INmune Bio is more favorable than Atara Biotherapeutics.

Earnings & Valuation

This table compares Atara Biotherapeutics and INmune Bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atara Biotherapeutics N/A N/A -$230.70 million ($5.27) -2.67
INmune Bio N/A N/A -$12.44 million N/A N/A

Profitability

This table compares Atara Biotherapeutics and INmune Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atara Biotherapeutics N/A -88.69% -77.83%
INmune Bio N/A N/A N/A

Summary

INmune Bio beats Atara Biotherapeutics on 6 of the 8 factors compared between the two stocks.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

About INmune Bio

INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.